AEMCOLO Drug Patent Profile

Which patents cover Aemcolo, and when can generic versions of Aemcolo launch?

Aemcolo is a drug marketed by Cosmo Technologies and is included in one NDA.

The generic ingredient in AEMCOLO is rifamycin sodium. There are eleven drug master file entries for this compound. Additional details are available on the rifamycin sodium profile page.

Summary for AEMCOLO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	54
Clinical Trials:	2
Patent Applications:	2,934
Drug Prices:	Drug price information for AEMCOLO
What excipients (inactive ingredients) are in AEMCOLO?	AEMCOLO excipients list
DailyMed Link:	AEMCOLO at DailyMed

See drug prices for AEMCOLO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AEMCOLO

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

210910

Dosage:

TABLET, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AEMCOLO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bradley A. Connor, M.D.	Phase 2
Bradley Connor	Phase 2
Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 2

See all AEMCOLO clinical trials

US Patents and Regulatory Information for AEMCOLO

AEMCOLO is protected by zero US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosmo Technologies	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		DISCN	Yes	No
Cosmo Technologies	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		DISCN	Yes	No

Expired US Patents for AEMCOLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosmo Technologies	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018
Cosmo Technologies	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018
Cosmo Technologies	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018
Cosmo Technologies	AEMCOLO	rifamycin sodium	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018

International Patents for AEMCOLO

See the table below for patents covering AEMCOLO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E392889
Canada	2569683	COMPOSITIONS PHARMACEUTIQUES ANTIMICROBIENNES ORALES (ORAL ANTIMICROBIAL PHARMCEUTICAL COMPOSITIONS)
Canada	2628005	COMPOSITIONS PHARMACEUTIQUES ANTIMICROBIENNES ORALES (ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS)
China	101317826	Oral antimicrobial pharmceutical compositions

Supplementary Protection Certificates for AEMCOLO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1763339	122019000048	Germany		PRODUCT NAME: RIFAMYCIN SV; NAT. REGISTRATION NO/DATE: 2200986.00.00 20190509; FIRST REGISTRATION: GB PL 08637/0028 20181218
1763339	C201930053	Spain		PRODUCT NAME: RIFAMICINA SV; NATIONAL AUTHORISATION NUMBER: 84120-DE/H/5379/001/DC; DATE OF AUTHORISATION: 20190628; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): PL 08637/0028; DATE OF FIRST AUTHORISATION IN EEA: 20181218
1763339	SPC/GB19/037	United Kingdom		PRODUCT NAME: RIFAMYCIN SV; REGISTERED: UK PL08637/0028 20181218

Last updated: July 12, 2026

Aemcolo (rifamycin) Market Dynamics and Financial Trajectory: Price, Volume, Exclusivity, and Generic Entry Risk

Aemcolo (rifamycin/chronic diarrhea agent) has a narrow, guideline-linked market tied to pediatric and adult indications for infectious diarrhea. Commercial trajectory is dominated by (1) payer restrictions and prior authorization patterns for “selected” infectious indications, (2) inventory and distribution constraints in the first two sales years, and (3) a patent and regulatory posture that limits early generic disruption but still faces entry risk from Paragraph IV challenges and/or line-extension formulations. The financial profile has tracked the typical pattern of a niche oral antibiotic: steep adoption in initial quarters, then revenue flattening with slower new prescriber growth unless differentiation expands through formulary access and expanded dose/adherence fit.

What is Aemcolo’s commercial positioning and how big is the addressable market?

Aemcolo is positioned as an oral rifamycin antibacterial used for treatment of travelers’ diarrhea due to noninvasive strains of enterotoxigenic E. coli (ETEC). Market access is influenced by a patient population that is (a) episodic, not chronic, and (b) often treated initially in urgent care, travel medicine, or retail settings where formulary status and day-one coverage drive prescribing.

Key market dynamics

• Acute, episodic demand: revenue is event-driven (travel seasonality, outbreaks, and patient travel schedules), not steady like chronic GI products.
• Guideline and stewardship constraints: payer utilization management tightens use to culture or empiric criteria aligned with noninvasive ETEC.
• Competing standards of care: fluoroquinolones, azithromycin, and rifaximin depending on geography, resistance patterns, and local stewardship.

Commercial exposure drivers

• Travelers’ diarrhea incidence and seasonality in the US.
• Formulary breadth at national PBMs and large integrated delivery networks.
• Uptake among urgent care and travel medicine prescribers versus GI specialists.

How does Aemcolo compare with standard-of-care antibiotics for travelers’ diarrhea?

Direct switching depends on resistance patterns and safety/contraindication profiles. In practice, Aemcolo competes on:

• oral convenience relative to some alternatives,
• stewardship optics associated with rifamycin class use,
• reduced systemic exposure relative to broader-spectrum systemic options (a common adoption lever in payer messaging).

How did Aemcolo revenue evolve after launch and what does the financial trajectory indicate?

Aemcolo’s post-launch financial trajectory has typically followed a niche antibiotic adoption curve:

• Early ramp: initial uptake as clinicians and payers validate “rifamycin for noninvasive traveler's diarrhea” as a distinct, covered option.
• Mid-stage plateau: revenue stabilization as prescriber penetration matures and payer step edits restrict use to eligible profiles.
• Growth pockets: seasonal spikes during travel periods and incremental gains when formulary status improves.

What are the main levers behind Aemcolo’s revenue path?

The revenue profile is most sensitive to four variables:

1. Formulary access: placement on managed formularies and reduction in prior authorization.
2. Net price: gross-to-net erosion driven by rebates and payer contracting.
3. Prescriber adoption velocity: new prescribers added through travel medicine and urgent care.
4. Supply continuity: oral antibiotic sales can swing with manufacturing or distribution interruptions.

What patent and exclusivity protections support Aemcolo’s sales, and when do they end?

Aemcolo’s market protection is tied to US patent coverage and any applicable regulatory exclusivities tied to the specific drug product and NDA approvals. These protections shape how quickly ANDA applicants or generic rifamycin competitors can enter without litigation.

What patents protect Aemcolo in the US?

A complete, litigation-ready mapping of Aemcolo’s US patent estate requires the Orange Book listing(s) associated with the approved Aemcolo NDA and their expiration dates, plus any listed method-of-use, formulation, and polymorph/process patents.

When does Aemcolo lose exclusivity?

The exclusivity timeline depends on:

• NDA exclusivity (if applicable),
• listed Orange Book patent expirations,
• any 5-year/3-year exclusivity layers tied to NDA amendments (where relevant).

Important market implication

• As patent cliffs approach, payer contracting pressure intensifies and wholesalers often build inventory ahead of launch windows, creating a short-term revenue pulse before generic erosion.

What generic entry risks exist for Aemcolo, including Paragraph IV challenges?

Generic risk is not purely theoretical for niche antibiotics. When the Orange Book lists multiple patents, the market can see:

• Paragraph IV filings against one or more patents,
• settlements that delay entry to a later date even if some patents are weak.

Which companies are positioned to challenge Aemcolo and file ANDAs?

Generic entrants typically compete on:

• bioequivalence feasibility,
• ability to match the specific drug product technology (formulation/process),
• litigation strategy on the strongest Orange Book patents.

What is the likely generic launch scenario for Aemcolo?

Common scenarios include:

• At-risk launch if litigation fails and the company enters immediately upon patent expiry or court decision.
• Settlement-driven entry date if parties agree to a delayed launch schedule.
• Product “workarounds” where formulation or dosing changes avoid infringement allegations (line extensions are sometimes used to reset certain IP boundaries).

What is the Orange Book status of Aemcolo (drug, patents, and listed exclusivities)?

Orange Book status is the single best predictor of:

• time-to-generic,
• the number of potential litigation targets,
• whether a generic entrant must design around formulation/method-of-use claims.

How many patents cover Aemcolo, and what types are they?

A robust estate analysis requires:

• number of listed patents,
• patent families and remaining term by jurisdiction,
• patent categories (composition of matter, formulation, method of treatment, and manufacturing/process).

What patent litigation affects Aemcolo’s future competition?

Patent litigation drives settlement timing and the probability of early generic erosion.

What settlements and court decisions have shaped Aemcolo’s timeline?

The practical effects:

• settlement agreements can set a binding entry date even if the generic would otherwise launch earlier,
• adverse rulings can accelerate entry and shift payer contracting behavior.

How does Aemcolo’s FDA and regulatory pathway affect competition (NDA vs. supplements)?

Aemcolo’s regulatory posture matters for:

• speed of generic approvals,
• the ability to launch “authorized generics” during litigation,
• the timing of label expansions that can extend coverage or reshape utilization.

What labeling scope drives utilization and payer coverage?

Utilization is affected by:

• label language defining eligible diarrhea pathogens and symptom criteria,
• pediatric inclusion,
• contraindications and safety warnings.

What formulation and manufacturing patents could block generic substitution?

Oral antibiotics often face:

• formulation patents (excipients, coatings, particle engineering),
• manufacturing-process patents (granulation, drying, blending parameters),
• polymorph or solid-state form claims (if relevant).

What barriers exist for ANDAs seeking to launch Aemcolo?

Generic feasibility depends on:

• whether the reference product has a protected formulation approach,
• whether bioequivalence is easily achievable or constrained by formulation technology,
• whether process claims create infringement exposure.

How do payer dynamics and contracting shape Aemcolo profitability?

Niche GI antibiotics can have attractive gross pricing but still underperform on net revenue due to contracting.

What drives gross-to-net in Aemcolo’s channel?

• PBM rebates and volume-based contracts,
• specialty pharmacy or distribution terms,
• patient assistance programs and hub participation where used,
• prior authorization and step therapy requiring documentation that slows script conversion.

What financial outcomes are most sensitive to Aemcolo’s market changes?

Aemcolo’s financial trajectory is most exposed to:

• generic timing: revenue erosion following at-risk or settled entry,
• net price changes: payer renegotiation in response to competitive supply,
• volume changes: seasonal travelers’ diarrhea fluctuations and prescriber adoption rate.

How would a generic entry reprice Aemcolo’s economics?

Generic launches typically trigger:

• rapid substitution in covered formularies,
• pricing compression and reduced gross-to-net stability,
• margin dilution for the branded product via contracting and increased promotional spend to defend share.

Key Takeaways

• Aemcolo’s market is niche and episodic, with revenue dominated by travel-linked demand and payer-controlled utilization.
• The financial trajectory is driven more by formulary access, net pricing, and supply continuity than by broad chronic disease growth.
• Generic and patent litigation risks increase as Orange Book term approaches; the number and type of listed patents determine how many hurdles generics face.
• In the final run-up to patent expiry, revenue can show short-term acceleration from inventory builds and payer channel stocking before erosion.

FAQs

1. How do step edits and prior authorization requirements impact Aemcolo prescriptions in commercial insurance?
2. What Orange Book patent categories typically drive the longest Aemcolo generic delay?
3. What settlement structures most commonly determine the entry date for Aemcolo ANDA applicants?
4. How do seasonal travelers’ diarrhea patterns influence Aemcolo quarterly revenue?
5. What formulation or manufacturing design-around strategies have historically succeeded for oral antibiotic ANDAs?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Labels and Prescribing Information for Aemcolo (rifamycin). U.S. Food and Drug Administration.
3. FDA Drug Approval Package for Aemcolo. U.S. Food and Drug Administration.